Compare GSK plc (GSK) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Immunovant Inc. Common Stock — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B). The key difference: GSK plc is far larger — about 14.7× Immunovant Inc. Common Stock's market cap, and GSK plc pays a 3.9% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Immunovant Inc. Common Stock for 1 Days on average.
| GSK | IMVT | |
|---|---|---|
Market Cap | $91.88B | $6.25B |
Volume | 7,730,529 | 1,755,411 |
Sector | Health | Health |
52-Week High | $61.18 | $44.96 |
52-Week Low | $43.24 | $17.03 |
Typical Hold Time | 93 Days | 1 Days |
Enterprise Value | $111.88B | $5.35B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
